The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan,Lingxiang Yu,Ning Zhang,Caiyun Peng,Guodong Su,Yi Jing,Linzhi Zhang,Tong Wu,Jiamin Cheng,Qian Guo,Xiaoliang Shi,Yinying Lu,,,,,,,,,,,,,
DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0661
2022-06-15
Abstract:Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China, severely threatens the life and health of patients. In recent years, precision medicine, clinical diagnoses, treatments, and innovative research have led to important breakthroughs in HCC care. The discovery of new biomarkers and the promotion of liquid biopsy technologies have greatly facilitated the early diagnosis and treatment of HCC. Progress in targeted therapy and immunotherapy has provided more choices for precise HCC treatment. Multiomics technologies, such as genomics, transcriptomics, and metabolomics, have enabled deeper understanding of the occurrence and development mechanisms, heterogeneity, and genetic mutation characteristics of HCC. The continued promotion and accurate typing of HCC, accurate guidance of treatment, and accurate prognostication have provided more treatment opportunities and prolonged survival timelines for patients with HCC. Innovative HCC research providing an in-depth understanding of the biological characteristics of HCC will be translated into accurate clinical practices for the diagnosis and treatment of HCC.
oncology,medicine, research & experimental